Dr. Subudhi on Future Directions With Immunotherapy in Prostate Cancer


In Partnership With:

Sumit K. Subudhi, MD, PhD, discusses future directions with immunotherapy in prostate cancer.

Sumit K. Subudhi, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses future directions with immunotherapy in prostate cancer.

CTLA-4 or PD-1/PD-L1 inhibitors appear to have a growing role in the treatment of men with prostate cancer, Subudhi explains. Pembrolizumab (Keytruda) is currently FDA approved for use in patients with unresectable or metastatic tumor mutational burden–high solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, which represents about 3% of all prostate cancers.

However, additional approvals for checkpoint inhibitors in combination with chemotherapy or other therapeutic interventions could emerge in prostate cancer, Subudhi says. Additionally, bispecific antibodies, which have garnered excitement in hematologic malignancies, are a potentially promising novel class of agents in prostate cancer, Subudhi concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine